These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 23010348)

  • 1. Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer.
    Wilson AJ; Lalani AS; Wass E; Saskowski J; Khabele D
    Gynecol Oncol; 2012 Dec; 127(3):579-86. PubMed ID: 23010348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
    Wu Y; Dong L; Bao S; Wang M; Yun Y; Zhu R
    Biomed Pharmacother; 2016 Dec; 84():462-469. PubMed ID: 27685789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thymoquinone enhances cisplatin-response through direct tumor effects in a syngeneic mouse model of ovarian cancer.
    Wilson AJ; Saskowski J; Barham W; Yull F; Khabele D
    J Ovarian Res; 2015 Jul; 8():46. PubMed ID: 26215403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells.
    Wilson AJ; Holson E; Wagner F; Zhang YL; Fass DM; Haggarty SJ; Bhaskara S; Hiebert SW; Schreiber SL; Khabele D
    Cancer Biol Ther; 2011 Sep; 12(6):484-93. PubMed ID: 21738006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reactive oxygen species-mediated synergistic and preferential induction of cell death and reduction of clonogenic resistance in breast cancer cells by combined cisplatin and FK228.
    Pluchino LA; Choudhary S; Wang HC
    Cancer Lett; 2016 Oct; 381(1):124-32. PubMed ID: 27477899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of the histone deacetylase inhibitor romidepsin (FK228) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21.
    Son DS; Wilson AJ; Parl AK; Khabele D
    Cancer Biol Ther; 2010 Jun; 9(11):928-35. PubMed ID: 20404564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
    Konstantinopoulos PA; Wilson AJ; Saskowski J; Wass E; Khabele D
    Gynecol Oncol; 2014 Jun; 133(3):599-606. PubMed ID: 24631446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the cytotoxicity of the Bithionol - cisplatin combination in a panel of human ovarian cancer cell lines.
    Ayyagari VN; Hsieh TJ; Diaz-Sylvester PL; Brard L
    BMC Cancer; 2017 Jan; 17(1):49. PubMed ID: 28086831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers.
    Yokoyama Y; Xin B; Shigeto T; Mizunuma H
    J Cancer Res Clin Oncol; 2011 Aug; 137(8):1219-28. PubMed ID: 21681689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SCCOHT tumors acquire chemoresistance and protection by interacting mesenchymal stroma/stem cells within the tumor microenvironment.
    Otte A; Yang Y; von der Ohe J; Melzer C; Hillemanns P; Feuerhake F; Hass R
    Int J Oncol; 2016 Dec; 49(6):2453-2463. PubMed ID: 27748897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thailandepsins are new small molecule class I HDAC inhibitors with potent cytotoxic activity in ovarian cancer cells: a preclinical study of epigenetic ovarian cancer therapy.
    Wilson AJ; Cheng YQ; Khabele D
    J Ovarian Res; 2012 Apr; 5(1):12. PubMed ID: 22531354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
    Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
    Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic induction of cancer cell death and reduction of clonogenic resistance by cisplatin and FK228.
    Choudhary S; Sood S; Wang HC
    Biochem Biophys Res Commun; 2013 Jun; 436(2):325-30. PubMed ID: 23743194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of AT-101/cisplatin overcomes chemoresistance by inducing apoptosis and modulating epigenetics in human ovarian cancer cells.
    Karaca B; Atmaca H; Bozkurt E; Kisim A; Uzunoglu S; Karabulut B; Sezgin C; Sanli UA; Uslu R
    Mol Biol Rep; 2013 Jun; 40(6):3925-33. PubMed ID: 23269627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gefitinib (ZD1839) increases the efficacy of cisplatin in ovarian cancer cells.
    Ohta T; Ohmichi M; Shibuya T; Takahashi T; Tsutsumi S; Takahashi K; Kurachi H
    Cancer Biol Ther; 2012 Apr; 13(6):408-16. PubMed ID: 22313686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitor, Romidepsin (FK228) inhibits endometrial cancer cell growth through augmentation of p53-p21 pathway.
    Li LH; Zhang PR; Cai PY; Li ZC
    Biomed Pharmacother; 2016 Aug; 82():161-6. PubMed ID: 27470351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
    Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noscapine Increases the Sensitivity of Drug-Resistant Ovarian Cancer Cell Line SKOV3/DDP to Cisplatin by Regulating Cell Cycle and Activating Apoptotic Pathways.
    Shen W; Liang B; Yin J; Li X; Cheng J
    Cell Biochem Biophys; 2015 May; 72(1):203-13. PubMed ID: 25510462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the cytotoxicity of the Bithionol-paclitaxel combination in a panel of human ovarian cancer cell lines.
    Ayyagari VN; Diaz-Sylvester PL; Hsieh TJ; Brard L
    PLoS One; 2017; 12(9):e0185111. PubMed ID: 28931042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Romidepsin (FK228) fails in counteracting the transformed phenotype of rhabdomyosarcoma cells but efficiently radiosensitizes, in┬ávitro and in┬ávivo, the alveolar phenotype subtype.
    Rossetti A; Petragnano F; Milazzo L; Vulcano F; Macioce G; Codenotti S; Cassandri M; Pomella S; Cicchetti F; Fasciani I; Antinozzi C; Di Luigi L; Festuccia C; De Felice F; Vergine M; Fanzani A; Rota R; Maggio R; Polimeni A; Tombolini V; Gravina GL; Marampon F
    Int J Radiat Biol; 2021; 97(7):943-957. PubMed ID: 33979259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.